You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolcapone
Accession NumberDB00323  (APRD00445)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia]
Structure
Thumb
Synonyms
(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone
3,4-Dihydroxy-5-nitro-4'-methylbenzophenone
4'-Methyl-3,4-dihydroxy-5-nitrobenzophenone
Tolcapon
Tolcapona
Tolcapone
Tolcaponum
External Identifiers
  • Ro 40-7592
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TasmarTablet, film coated200 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mg/1OralValeant Pharmaceuticals North America LLC2004-07-27Not applicableUs
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated200 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated200 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet100 mgOralHoffmann La Roche Limited1997-10-201999-01-11Canada
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet, film coated100 mgOralMeda Ab1997-08-27Not applicableEu
TasmarTablet200 mgOralHoffmann La Roche Limited1997-10-201999-01-11Canada
TolcaponeTablet, film coated100 mg/1OralOceanside Pharmaceuticals2004-07-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TolcaponeTablet, coated100 mg/1OralPar Pharmaceutical Inc.2015-01-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Sen De NingDexin Runsheng Pharmaceutical
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICIF6334OLY
CAS number134308-13-7
WeightAverage: 273.2408
Monoisotopic: 273.063722467
Chemical FormulaC14H11NO5
InChI KeyMIQPIUSUKVNLNT-UHFFFAOYSA-N
InChI
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
IUPAC Name
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol
SMILES
CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
Pharmacology
IndicationUsed as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.
Structured Indications
PharmacodynamicsTolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa.
Mechanism of actionThe precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome.
TargetKindPharmacological actionActionsOrganismUniProt ID
Catechol O-methyltransferaseProteinyes
inhibitor
HumanP21964 details
Related Articles
AbsorptionRapidly absorbed (absolute bioavailability is about 65%)
Volume of distribution
  • 9 L
Protein binding> 99.9% (to serum albumin)
Metabolism

The main metabolic pathway of tolcapone is glucuronidation

Route of eliminationTolcapone is almost completely metabolized prior to excretion, with only a very small amount (0.5% of dose) found unchanged in urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile.
Half life2-3.5 hours
Clearance
  • 7 L/h
ToxicityLD50 = 1600 mg/kg (Orally in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Tolcapone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tolcapone.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Tolcapone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tolcapone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tolcapone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tolcapone.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tolcapone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tolcapone.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolcapone.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tolcapone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tolcapone.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Tolcapone.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tolcapone.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tolcapone.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tolcapone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Tolcapone.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolcapone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tolcapone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tolcapone.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Tolcapone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tolcapone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tolcapone.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolcapone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Tolcapone.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Tolcapone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Tolcapone.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Tolcapone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolcapone.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tolcapone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tolcapone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tolcapone.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Tolcapone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tolcapone.Vet Approved
AzelastineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolcapone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tolcapone.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Tolcapone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tolcapone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tolcapone.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolcapone.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tolcapone.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tolcapone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tolcapone.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Tolcapone.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Tolcapone.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Tolcapone.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Tolcapone.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Tolcapone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tolcapone.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolcapone.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tolcapone.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tolcapone.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolcapone.Approved, Investigational
BuprenorphineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tolcapone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tolcapone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tolcapone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tolcapone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tolcapone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tolcapone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolcapone.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Tolcapone.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolcapone.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tolcapone.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tolcapone.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolcapone.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tolcapone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Caroxazone.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Tolcapone.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Tolcapone.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tolcapone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tolcapone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tolcapone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tolcapone.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tolcapone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolcapone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tolcapone.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tolcapone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolcapone.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tolcapone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tolcapone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tolcapone.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Tolcapone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tolcapone.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tolcapone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tolcapone.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tolcapone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tolcapone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tolcapone.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolcapone.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Tolcapone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Tolcapone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tolcapone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tolcapone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolcapone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tolcapone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tolcapone.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tolcapone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolcapone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tolcapone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tolcapone.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tolcapone.Approved
DiethylstilbestrolThe metabolism of Diethylstilbestrol can be decreased when combined with Tolcapone.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolcapone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tolcapone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolcapone.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Tolcapone.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tolcapone.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolcapone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolcapone.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tolcapone.Approved
DobutamineThe metabolism of Dobutamine can be decreased when combined with Tolcapone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Tolcapone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tolcapone.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tolcapone.Approved
DoxepinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tolcapone.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tolcapone.Experimental, Illicit
DuloxetineTolcapone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tolcapone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tolcapone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Tolcapone.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Tolcapone.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolcapone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolcapone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tolcapone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Tolcapone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Tolcapone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolcapone.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Tolcapone.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tolcapone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tolcapone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tolcapone.Approved
EthanolTolcapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tolcapone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tolcapone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tolcapone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tolcapone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tolcapone.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tolcapone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tolcapone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tolcapone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Tolcapone.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tolcapone.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tolcapone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tolcapone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolcapone.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tolcapone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tolcapone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tolcapone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tolcapone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tolcapone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tolcapone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tolcapone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolcapone.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tolcapone.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Tolcapone.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tolcapone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tolcapone is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tolcapone.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tolcapone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tolcapone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tolcapone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tolcapone.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tolcapone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydracarbazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Tolcapone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tolcapone.Approved, Vet Approved
HydrocodoneTolcapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tolcapone.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tolcapone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolcapone.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Tolcapone.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Tolcapone.Withdrawn
IproclozideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolcapone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tolcapone.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tolcapone.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tolcapone.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Tolcapone.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Tolcapone.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolcapone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tolcapone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tolcapone.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Tolcapone.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Tolcapone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tolcapone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tolcapone.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tolcapone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocetirizine.Approved
LevodopaTolcapone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tolcapone.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolcapone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tolcapone.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tolcapone.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolcapone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tolcapone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tolcapone.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Tolcapone.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tolcapone.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tolcapone.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tolcapone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tolcapone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Tolcapone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolcapone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tolcapone.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tolcapone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tolcapone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tolcapone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tolcapone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tolcapone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tolcapone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tolcapone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tolcapone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Tolcapone.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tolcapone.Approved
MethotrimeprazineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tolcapone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tolcapone.Approved
MethyldopaThe metabolism of Methyldopa can be decreased when combined with Tolcapone.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tolcapone.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Tolcapone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Tolcapone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Tolcapone.Approved, Investigational
MetyrosineTolcapone may increase the sedative activities of Metyrosine.Approved
MicafunginThe metabolism of Micafungin can be decreased when combined with Tolcapone.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Tolcapone is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tolcapone.Approved
MirtazapineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moclobemide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolcapone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tolcapone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tolcapone.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Tolcapone.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Tolcapone.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolcapone.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Tolcapone.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Tolcapone.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tolcapone.Approved
NicorandilNicorandil may increase the hypotensive activities of Tolcapone.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Tolcapone.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Tolcapone.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tolcapone.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Tolcapone.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tolcapone.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tolcapone.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tolcapone.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tolcapone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tolcapone.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tolcapone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tolcapone.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tolcapone.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolcapone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tolcapone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tolcapone.Approved, Illicit
OrphenadrineTolcapone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tolcapone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tolcapone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tolcapone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tolcapone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolcapone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolcapone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolcapone.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tolcapone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Tolcapone.Approved
ParaldehydeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Tolcapone.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tolcapone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
PerazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolcapone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tolcapone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tolcapone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolcapone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tolcapone.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tolcapone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tolcapone.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenoxypropazine.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Tolcapone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tolcapone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tolcapone.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Tolcapone.Approved
PipamperoneThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Tolcapone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.Approved
PramipexoleTolcapone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tolcapone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tolcapone.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Tolcapone.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tolcapone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tolcapone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tolcapone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tolcapone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tolcapone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tolcapone.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Tolcapone.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tolcapone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tolcapone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tolcapone.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolcapone.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolcapone.Approved
RasagilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolcapone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tolcapone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tolcapone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Tolcapone.Approved
RisperidoneTolcapone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tolcapone.Vet Approved
RopiniroleTolcapone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone.Approved
RotigotineTolcapone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tolcapone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tolcapone.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolcapone.Approved
SafrazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Tolcapone is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tolcapone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tolcapone.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolcapone.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Tolcapone.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Tolcapone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Tolcapone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tolcapone is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tolcapone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tolcapone.Approved
SuvorexantTolcapone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Tolcapone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tasimelteon.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolcapone.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tolcapone.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Tolcapone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tolcapone.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tolcapone.Investigational
ThalidomideTolcapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tolcapone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tolcapone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tolcapone.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tolcapone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tolcapone.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Tolcapone.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Tolcapone.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Tolcapone is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tolcapone.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Tolcapone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolcapone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolcapone.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tolcapone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Tolcapone.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tolcapone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolcapone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tolcapone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Tolcapone is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tolcapone.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolcapone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Tolcapone.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tolcapone.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tolcapone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tolcapone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tolcapone.Vet Approved
ZolpidemTolcapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tolcapone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tolcapone.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolcapone.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075 ]
  2. Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329 ]
  3. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773 ]
  4. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  5. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
External Links
ATC CodesN04BX01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (71.3 KB)
MSDSDownload (17.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9041
Blood Brain Barrier-0.9418
Caco-2 permeable-0.5422
P-glycoprotein substrateNon-substrate0.6612
P-glycoprotein inhibitor INon-inhibitor0.6371
P-glycoprotein inhibitor IINon-inhibitor0.9128
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.6554
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateSubstrate0.5245
CYP450 1A2 substrateNon-inhibitor0.9199
CYP450 2C9 inhibitorInhibitor0.8317
CYP450 2D6 inhibitorNon-inhibitor0.9135
CYP450 2C19 inhibitorNon-inhibitor0.8762
CYP450 3A4 inhibitorNon-inhibitor0.6585
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5984
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6079
BiodegradationNot ready biodegradable0.9433
Rat acute toxicity2.2574 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8346
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral200 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral100 mg
Tablet, film coatedOral200 mg
Tablet, coatedOral100 mg/1
Prices
Unit descriptionCostUnit
Tasmar 100 mg tablet8.13USD tablet
Tasmar 200 mg tablet7.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5236952 No1995-01-292012-01-29Us
US5476875 No1992-12-192012-12-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0569 mg/mLALOGPS
logP2.63ALOGPS
logP3.28ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)5.17ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.35 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.96 m3·mol-1ChemAxon
Polarizability26.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • Nitrophenol derivative
  • Nitrobenzene
  • Acetophenone
  • Aryl ketone
  • 1,2-diphenol
  • Benzoyl
  • Toluene
  • Phenol
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Ketone
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K: Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clin Neuropharmacol. 2010 May;33(3):142-50. doi: 10.1097/WNF.0b013e3181d99d6f. [PubMed:20502133 ]
  3. Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. [PubMed:9917075 ]
  4. Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. [PubMed:15697329 ]
  5. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. [PubMed:19503773 ]
  6. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR: Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007 May;32(5):1011-20. Epub 2006 Oct 25. [PubMed:17063156 ]
  7. Stocchi F, De Pandis MF: Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging. 2006;1(4):317-25. [PubMed:18046910 ]
  8. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [PubMed:12538800 ]
  9. Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [PubMed:11873938 ]
  10. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [PubMed:10882160 ]
  11. Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [PubMed:9808337 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23